Scarica l'app Stockscreener
210.39
0.18%
-0.38
Dopo l'orario di chiusura:
209.61
-0.78
-0.37%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie Inc stock (US00287Y1091): earnings momentum and pipeline keep big pharma name in focus - AD HOC NEWS
AbbVie Inc. stock (US00287Y1091): Pipeline, Humira transition and US market exposure - AD HOC NEWS
ABBV Maintains Rating by Evercore ISI Group -- Price Target Lowe - GuruFocus
Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie? - The Globe and Mail
AbbVie stock (US00287Y1091): earnings beat and dividend keep focus on pipeline - AD HOC NEWS
How Important Are Skyrizi and Rinvoq to AbbVie's Q1 Results? - The Globe and Mail
Mubadala Investment Co Pjsc Raises Share Stake In Abbvie, Match Group,Cuts In CVS Health - TradingView
AbbVie Stock Is Up 22% Over the Past Year. Analysts See 37% Upside to $289 Target - TIKR.com
We Think You Can Look Beyond AbbVie's (NYSE:ABBV) Lackluster Earnings - simplywall.st
AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear - Yahoo Finance
Evercore ISI Adjusts Price Target on AbbVie to $235 From $236, Maintains Outperform Rating - marketscreener.com
2 Reasons to Like ABBV and 1 to Stay Skeptical - TradingView
FDA Approval Gives BeOne Medicines a New Challenger to AbbVie, Roche Cancer Drug - MedCity News
BeiGene Must Face AbbVie's Chemical Trade Secret Claims - Law360
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
Jim Cramer Reveals AbbVie’s (ABBV) “Good Stuff” - Insider Monkey
AbbVie stock (US00287Y1091): Business model and key drivers for US investors - AD HOC NEWS
ABBV Maintained by Piper Sandler -- Price Target Raised to $298 - GuruFocus
Piper Sandler raises Abbvie stock price target on pipeline depth By Investing.com - Investing.com Canada
BofA Securities Upgrades AbbVie(ABBV.US) to Buy Rating, Raises Target Price to $234 - Moomoo
Piper Sandler Adjusts Price Target on AbbVie to $298 From $294, Maintains Overweight Rating - Moomoo
AbbVie stock (US00287Y1091): Q1 earnings beat and guidance raise drive 3.1% gain - AD HOC NEWS
BeiGene Can’t Toss AbbVie Trade Secrets Suit Over Cancer Therapy - Bloomberg Law News
AbbVie stock (US00287Y1091): Rises 3.3% on 2026 outlook and AGM results - AD HOC NEWS
The Zacks Analyst Blog NVIDIA, Mastercard, AbbVie, Waterstone and Precipio - Zacks Investment Research
Goldman Sachs Large Cap Equity Fund's AbbVie Inc(ABBV) Holding History - GuruFocus
CFO CAPITAL MANAGEMENT LLC's AbbVie Inc(ABBV) Holding History - GuruFocus
A Look At AbbVie (ABBV) Valuation After New Immunology Data And Upgraded 2026 Earnings Outlook - Yahoo Finance
AbbVie Inc. 8-K SEC Filing May 2026: Common Stock and Senior Notes Registered on NYSE - Minichart
AbbVie Inc. (ABBV) Announces Results of 2026 Annual Meeting of S - GuruFocus
AbbVie Shareholders Back Directors, Maintain Governance Structure - TipRanks
AbbVie Inc (ABBV) Stock Up 3.1% and Still Undervalued -- GF Scor - GuruFocus
[Form 4] AbbVie Inc. Insider Trading Activity - Stock Titan
[8-K] AbbVie Inc. Reports Material Event - Stock Titan
Why AbbVie Inc. (ABBV) is One of the Best Healthcare Stocks to Buy for the Long Term - Insider Monkey
AbbVie (NYSE: ABBV) director gains 1,118-share equity award - Stock Titan
AbbVie (ABBV) director Jennifer L. Davis granted 1,118 restricted stock units as equity pay - Stock Titan
Top Stock Reports for NVIDIA, Mastercard & AbbVie - Yahoo Finance
3 reasons to buy AbbVie stock (ABBV) like there's no tomorrow - MSN
AbbVie rises 3.3% as upbeat 2026 outlook and fresh analyst optimism lift sentiment - Quiver Quantitative
3 Reasons to Buy AbbVie Stock (ABBV) Like There's No Tomorrow - The Motley Fool
AbbVie’s Growth Engine Is Firing On All Cylinders (NYSE:ABBV) - Seeking Alpha
AbbVie (ABBV) Receives a Buy from Berenberg Bank - The Globe and Mail
AbbVie Stock Deserves A Higher Multiple (NYSE:ABBV) - Seeking Alpha
A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried? - The Motley Fool
A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried? - The Motley Fool
United Financial Planning Group LLC's AbbVie Inc(ABBV) Holding History - GuruFocus
Enanta Pharma Q2 loss narrows on higher AbbVie royalties, lower costs - TradingView
AbbVie shares consolidate as technicals point to continued selling pressure: weekly report - Traders Union
AbbVie Q1: Skyrizi Delivers, Here's What Skeptics Are Missing - Seeking Alpha
AbbVie Stock: Is Wall Street Bullish or Bearish? - Barchart.com
ABBV Stock Price, Quote & Chart | ABBVIE INC (NYSE:ABBV) - ChartMill
AbbVie Inc. stock (US00287Y1091): Post-Humira growth and raised 2026 guidance - AD HOC NEWS
AbbVie Q1 earnings loom: Buy or sell the stock ahead of results? - MSN
1.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):